A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : pCR

Search Conditions:
Search Keyword : pCR
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: pCR
Appearance Frequency: 2219 time(s)
Long forms: 39

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
pathologic complete response
(2061 times)
Neoplasms
(1403 times)
NAC (291 times)
OS (284 times)
DFS (203 times)
1987 The treatment of advanced stage ovarian carcinoma with a combination of chemotherapy, radiotherapy, and radiosensitizer: report of a pilot study from the National Cancer Institute.
pathologic response
(85 times)
Neoplasms
(57 times)
OS (13 times)
DFS (10 times)
CRT (7 times)
1998 [Coexistence of ovarian adenocarcinoma with tubal pregnancy and plano-epithelial cervical cancer of uterus].
pathologic CR
(20 times)
Neoplasms
(13 times)
CR (10 times)
cCR (8 times)
PR (5 times)
1996 [Treatment of advanced testis cancer with a high dose chemotherapy regimen (PVeBV)].
pathological remission
(9 times)
Neoplasms
(4 times)
MALT (5 times)
DFS (2 times)
LAPC (2 times)
2001 [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
pathologically confirmed complete remissions
(3 times)
General Surgery
(1 time)
EC (1 time)
FIGO (1 time)
GRCSG (1 time)
1988 Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy.
Patients with a complete histopathological response
(3 times)
Neoplasms
(2 times)
cCR (1 time)
HT (1 time)
Ir-192 HDR (1 time)
1994 Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Pathologic response was denoted as complete
(2 times)
Nuclear Medicine
(1 time)
DFS (1 time)
LABC (1 time)
NeoChemo (1 time)
2010 Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
pathological response was complete
(2 times)
Neoplasms
(1 time)
5-FU (1 time)
DT (1 time)
LABC (1 time)
2010 Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Patients with complete response
(2 times)
Molecular Biology
(1 time)
DSB (1 time)
ICT (1 time)
LRR (1 time)
2016 Local Recurrence in the Lateral Lymph Node Compartment: Improved Outcomes with Induction Chemotherapy Combined with Multimodality Treatment.
10  plain chest radiography
(2 times)
Diagnostic Imaging
(1 time)
COPD (1 time)
CT (1 time)
I/E (1 time)
1997 Utility of low-dose helical CT as a second step after plain chest radiography for mass screening for lung cancer.
11  polymerase chain reaction
(2 times)
Antineoplastic Agents
(1 time)
Ab (1 time)
CAP (1 time)
MBE (1 time)
2009 Acinetobacter baumannii: emergence of four strains with novel bla(OXA-51-like) genes in patients with diabetes mellitus.
12  improve complete response rates
(1 time)
Neoplasms
(1 time)
CSS (1 time)
DFS (1 time)
OS (1 time)
2013 Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
13  P wave complexity ratio
(1 time)
Cardiology
(1 time)
AF (2 times)
CABG (1 time)
PD (1 time)
2004 Preoperative electrocardiographic risk assessment of atrial fibrillation after coronary artery bypass grafting.
14  para-cresol
(1 time)
Biophysics
(1 time)
Ph (1 time)
2013 Molecular-level understanding of ground- and excited-state O-H...O hydrogen bonding involving the tyrosine side chain: a combined high-resolution laser spectroscopy and quantum chemistry study.
15  pathologic examination of the resection specimen
(1 time)
General Surgery
(1 time)
CI (1 time)
DR (1 time)
EAC (1 time)
2015 Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
16  Pathologic response to chemotherapy
(1 time)
Neoplasms
(1 time)
AA (1 time)
HR (1 time)
OS (1 time)
2015 Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.
17  Pathologic response to induction was complete
(1 time)
General Surgery
(1 time)
NSCLC (1 time)
2014 Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet.
18  pathological clinical response
(1 time)
Neoplasms
(1 time)
FCGR2A (1 time)
2015 FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
19  pathological complete primary tumor response
(1 time)
Neoplasms
(1 time)
HR (1 time)
pN0 (1 time)
2010 [Role of lymph node irradiation in breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy: the Rene-Huguenin Cancer Center experience].
20  pathological complete response in breast and lymph nodes
(1 time)
Breast Neoplasms
(1 time)
--- 2016 Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
21  pathological evidence of disease in the breast
(1 time)
Neoplasms
(1 time)
cCR (1 time)
2002 The surgical management of patients following neoadjuvant chemotherapy for locally advanced breast cancer.
22  Pathological response rates were as follows: Complete
(1 time)
Neoplasms
(1 time)
--- 2006 Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma.
23  Pathological response was classified as no residual tumor
(1 time)
Gynecology
(1 time)
LACA (1 time)
NACT (1 time)
TAP (1 time)
2014 Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma.
24  pathological response was classified into either a complete response
(1 time)
Diagnostic Imaging
(1 time)
ADC (1 time)
DWI (1 time)
MRI (1 time)
2015 Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
25  Pathological responses were considered complete
(1 time)
Neoplasms
(1 time)
npCR (1 time)
2005 Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
26  pathologically after surgery
(1 time)
Gastroenterology
(1 time)
cCR (1 time)
ESCP (1 time)
2018 Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery.
27  pathologically confirmed CR
(1 time)
Neoplasms
(1 time)
CRs (1 time)
EAP (1 time)
PRs (1 time)
1989 Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.
28  pathologically diagnosed as necrosis/fibrosis or teratoma
(1 time)
Urology
(1 time)
psCR (1 time)
RPLND (1 time)
1999 [Clinical study of retroperitoneal lymph node dissection for patients with advanced germ cell tumors].
29  Pathologically, complete response was confirmed
(1 time)
Antineoplastic Agents
(1 time)
--- 2007 [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
30  patients underwent ALND after chemotherapy, and complete axillary response
(1 time)
General Surgery
(1 time)
ALND (1 time)
FDG (1 time)
NAC (1 time)
2013 Early assessment of axillary response with ⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
31  Patients were classified into complete
(1 time)
General Surgery
(1 time)
EAC (1 time)
2017 Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
32  patients, mainly with chemotherapy induced surgicopathological complete remission
(1 time)
Cardiology
(1 time)
--- 2001 Small cell lung cancer I--III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy.
33  postchemoradiotherapy
(1 time)
Neoplasms
(1 time)
--- 2005 Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
34  Primary endpoints were efficacy, determined by histopathological complete response
(1 time)
Neoplasms
(1 time)
AEs (1 time)
cetux-RT (1 time)
SAEs (1 time)
2014 Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
35  proportional odds structure
(1 time)
Statistics as Topic
(1 time)
CR (1 time)
KM (1 time)
2015 Sparse kernel machine regression for ordinal outcomes.
36  proven complete remission
(1 time)
Neoplasms
(1 time)
cT (1 time)
HRS (1 time)
2003 Remission rates in breast cancer treated with preoperative chemotherapy and radiotherapy.
37  proven histologically at laparotomy
(1 time)
Neoplasms
(1 time)
CR (1 time)
ORR (1 time)
PR (1 time)
1997 Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
38  pulmonary metastases as either complete lack of residual lesions
(1 time)
Hematology
(1 time)
CI (1 time)
CR (1 time)
CWS (1 time)
2017 The prognostic value of early radiographic response in children and adolescents with embryonal rhabdomyosarcoma stage IV, metastases confined to the lungs: A report from the Cooperative Weichteilsarkom Studiengruppe (CWS).
39  therapy.Pathologic complete response
(1 time)
General Surgery
(1 time)
CEA (1 time)
2010 [Clinical pathologic factors predicting tumor response after preoperative neoadjuvant therapy for rectal cancer].